Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods: 2021-2024

Historic Finished Goods for Apellis Pharmaceuticals (APLS) over the last 2 years, with Mar 2024 value amounting to $13.0 million.

  • Apellis Pharmaceuticals' Finished Goods rose 325.22% to $13.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $13.0 million, marking a year-over-year increase of 325.22%. This contributed to the annual value of $30.7 million for FY2023, which is 1639.18% up from last year.
  • According to the latest figures from Q1 2024, Apellis Pharmaceuticals' Finished Goods is $13.0 million, which was down 57.57% from $30.7 million recorded in Q4 2023.
  • Apellis Pharmaceuticals' 5-year Finished Goods high stood at $30.7 million for Q4 2023, and its period low was $479,000 during Q4 2021.
  • Its 3-year average for Finished Goods is $10.4 million, with a median of $3.1 million in 2023.
  • Data for Apellis Pharmaceuticals' Finished Goods shows a peak YoY skyrocketed of 2,909.64% (in 2023) over the last 5 years.
  • Over the past 4 years, Apellis Pharmaceuticals' Finished Goods (Quarterly) stood at $479,000 in 2021, then spiked by 268.68% to $1.8 million in 2022, then soared by 1,639.18% to $30.7 million in 2023, then surged by 325.22% to $13.0 million in 2024.
  • Its Finished Goods stands at $13.0 million for Q1 2024, versus $30.7 million for Q4 2023 and $20.3 million for Q3 2023.